Physician profile
Madeeha Saeed
NPI 1851554265
$6,853.98
in general payments reported to CMS, 2019-2025
38 companies · $438 in 2025
The $438 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $573 · 2021: $771 · 2022: $1,724 · 2023: $2,196 · 2024: $658 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831 · Travel and Lodging: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.83 |
| Travel and Lodging | $461.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,069.72 | 2020-2025 | Diamondback Peripheral, Supera, Ensite Precision |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $655.18 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $614.04 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $555.72 | 2019-2024 | Jardiance |
| Preventric Diagnostics, INC. | $552.17 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $512.96 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Janssen Pharmaceuticals, INC | $364.19 | 2019-2024 | Xarelto |
| Amgen INC. | $357.07 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $267.15 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $222.31 | 2019-2024 | |
| Medtronic, INC. | $188.98 | 2021-2025 | Abre, Corevalve Evolut R |
| Novo Nordisk INC | $181.99 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $169.66 | 2019-2025 | |
| Edwards Lifesciences Corporation | $148.66 | 2019 | |
| Baxter Healthcare | $103.17 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeeha Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.